ITRM980061A0 - Procedimento per la produzione di peptidi com proprieta' inibitrici della sintesi ns3 del virus hcv peptidi cosi' ottenibili e peptidi - Google Patents

Procedimento per la produzione di peptidi com proprieta' inibitrici della sintesi ns3 del virus hcv peptidi cosi' ottenibili e peptidi

Info

Publication number
ITRM980061A0
ITRM980061A0 IT98RM000061A ITRM980061A ITRM980061A0 IT RM980061 A0 ITRM980061 A0 IT RM980061A0 IT 98RM000061 A IT98RM000061 A IT 98RM000061A IT RM980061 A ITRM980061 A IT RM980061A IT RM980061 A0 ITRM980061 A0 IT RM980061A0
Authority
IT
Italy
Prior art keywords
peptides
obtainable
synthesis
production
inhibiting properties
Prior art date
Application number
IT98RM000061A
Other languages
English (en)
Inventor
Antonello Pessi
Francesco Raffaele De
Christian Steinkuhler
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Priority to IT98RM000061A priority Critical patent/IT1299134B1/it
Publication of ITRM980061A0 publication Critical patent/ITRM980061A0/it
Priority to CA002319306A priority patent/CA2319306A1/en
Priority to JP2000529354A priority patent/JP2002509075A/ja
Priority to PCT/IT1999/000022 priority patent/WO1999038888A2/en
Priority to AU25450/99A priority patent/AU2545099A/en
Priority to EP99905173A priority patent/EP1053249A2/en
Publication of ITRM980061A1 publication Critical patent/ITRM980061A1/it
Application granted granted Critical
Publication of IT1299134B1 publication Critical patent/IT1299134B1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT98RM000061A 1998-02-02 1998-02-02 Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi IT1299134B1 (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IT98RM000061A IT1299134B1 (it) 1998-02-02 1998-02-02 Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
CA002319306A CA2319306A1 (en) 1998-02-02 1999-02-02 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
JP2000529354A JP2002509075A (ja) 1998-02-02 1999-02-02 Ｈｃｖのｎｓ３タンパク質に関連したセリンプロテアーゼ活性のペプチド阻害剤、関連する使用およびその製造方法
PCT/IT1999/000022 WO1999038888A2 (en) 1998-02-02 1999-02-02 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
AU25450/99A AU2545099A (en) 1998-02-02 1999-02-02 Peptide inhibitors of the serine protease activity associated to the ns3 proteinof hcv, relevant uses and process of production
EP99905173A EP1053249A2 (en) 1998-02-02 1999-02-02 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000061A IT1299134B1 (it) 1998-02-02 1998-02-02 Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi

Publications (3)

Publication Number Publication Date
ITRM980061A0 true ITRM980061A0 (it) 1998-02-02
ITRM980061A1 ITRM980061A1 (it) 1999-08-02
IT1299134B1 IT1299134B1 (it) 2000-02-29

Family

ID=11405519

Family Applications (1)

Application Number Title Priority Date Filing Date
IT98RM000061A IT1299134B1 (it) 1998-02-02 1998-02-02 Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi

Country Status (6)

Country Link
EP (1) EP1053249A2 (it)
JP (1) JP2002509075A (it)
AU (1) AU2545099A (it)
CA (1) CA2319306A1 (it)
IT (1) IT1299134B1 (it)
WO (1) WO1999038888A2 (it)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
GB9925955D0 (en) * 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
JP2005535574A (ja) 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
DE60336550D1 (de) 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
EP1506000B9 (en) 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CN1791599A (zh) 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7642235B2 (en) 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
RU2006115558A (ru) 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
EP2407470A3 (en) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
EP2311851A3 (en) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2006021896A2 (en) * 2004-08-27 2006-03-02 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
WO2006109196A2 (en) * 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
BRPI0613962A2 (pt) 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
WO2007016441A1 (en) 2005-08-01 2007-02-08 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
US20070105781A1 (en) 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US7632821B2 (en) 2005-08-09 2009-12-15 Merck & Co., Inc. Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
ES2344156T3 (es) 2005-08-19 2010-08-19 Vertex Pharmaceuticals Incorporated Procedimientos e intermedios.
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
EP2392589A3 (en) 2005-11-11 2012-06-20 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2079480B1 (en) 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2076278B1 (en) 2006-10-24 2015-05-06 Merck Sharp & Dohme Corp. Macrocyclic HCV NS3 protease inhibitors
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
MX2009004556A (es) 2006-10-27 2009-07-10 Merck & Co Inc Inhibidores de la proteasa ns3 del hcv.
CN101568346B (zh) 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
CN103224506A (zh) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008137126A2 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of hcv infection
TW200914013A (en) 2007-06-29 2009-04-01 Gilead Sciences Inc Antiviral compounds
AP2874A (en) 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
WO2009033725A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US8461107B2 (en) 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
SI2310095T1 (sl) 2008-07-22 2013-01-31 Merck Sharp & Dohme Corp. Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US20140356325A1 (en) 2012-01-12 2014-12-04 Ligand Pharmaceuticals Incorporated Novel 2'-c-methyl nucleoside derivative compounds
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
EP0907659A1 (en) * 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
ES2241157T3 (es) * 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.

Also Published As

Publication number Publication date
CA2319306A1 (en) 1999-08-05
IT1299134B1 (it) 2000-02-29
ITRM980061A1 (it) 1999-08-02
WO1999038888A2 (en) 1999-08-05
EP1053249A2 (en) 2000-11-22
AU2545099A (en) 1999-08-16
WO1999038888A3 (en) 1999-10-07
JP2002509075A (ja) 2002-03-26

Similar Documents

Publication Publication Date Title
ITRM980061A0 (it) Procedimento per la produzione di peptidi com proprieta' inibitrici della sintesi ns3 del virus hcv peptidi cosi' ottenibili e peptidi
ITRM940092A0 (it) Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
DE60040101D1 (de) Prozesskammerkühlung
EP1113777A4 (en) NOVEL HEPATITIS C VIRUS PEPTIDES AND USES THEREOF
IT1310855B1 (it) Procedimento per la realizzazione di decori di manufatti ceramici edecoro cosi' ottenuto
TH33394EX (th) เข็มกลัด
TH45057EX (th) กรอบรูป
TH40263EX (th) เก้าอี้
TH51635EX (th) ขวด
TH39442EX (th) แปรงสีฟัน
TH40669EX (th) แปรงสีฟัน
TH52851EX (th) กรอบรูป
TH52853EX (th) กรอบรูป
TH50477EX (th) "เข็มกลัด"
TH50478EX (th) "เข็มกลัด"
TH50480EX (th) เข็มกลัด
TH43545EX (th) กรอบรูป
ITMI952366A1 (it) Capo di abbigliamento perfezionato, in particolare del tipo definito comunemente gilet
TH43537EX (th) กรอบรูป
TH45058EX (th) กรอบรูป
TH42346EX (th) (เก้าอี้)
TH50236EX (th) เก้าอี้
GB0000953D0 (en) Recombinant virus assays used for the elucidation of the molecular mode of action of antiviral drugs
TH40374EX (th) เก้าอี้
TH40372EX (th) เก้าอี้

Legal Events

Date Code Title Description
0001 Granted